Drug Trial Radar · NCT05467033
Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin
Last checked: Nov 19, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
424
Planned (sponsor's estimate)
Start
Sep 1, 2022
Primary completion
Aug 31, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Medical University of BialystokAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a randomized, multicenter, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 6 Hospital Nephrology Departments to evaluate the safety and effectiveness of desmopressin on the prevention of bleeding after percutaneous needle kidney biopsy in patients with rare and ultrarare glomerulonephritis.
Conditions
- Kidney Biopsy
Interventions
DesmopressinDrug
desmopressin 0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;
intravenous infusion NaClDrug
0,9% NaCl managed as intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bleeding events in 24 hours after the procedureTime frame: 24 hours after kidney biopsy
- Bleeding events in 48 hours after the procedureTime frame: 48 hours after kidney biopsy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
II Department of Nephrology and Hypertension
Bialystok, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.